相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Zobair Younossi et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Samer Gawrieh et al.
CLINICS IN LIVER DISEASE (2018)
Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2018)
Increasing trend for Hepatocellular Carcinoma (HCC) linked to Nonalcoholic Fatty Liver Disease (NAFLD) in the United States
E. Miller et al.
JOURNAL OF HEPATOLOGY (2018)
Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes
Chin-Hsiao Tseng
LIVER INTERNATIONAL (2018)
Prognostic value of metformin for non-small cell lung cancer patients with diabetes
Tongbai Xu et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2018)
Metformin selectively targets redox control of complex I energy transduction
Amy R. Cameron et al.
REDOX BIOLOGY (2018)
Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases
Jonathan G. Stine et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease
Fasiha Kanwal et al.
GASTROENTEROLOGY (2018)
NAFLD and diabetes mellitus
Herbert Tilg et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial
Amir Sonnenblick et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients
Shujuan Ma et al.
MEDICINE (2017)
Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
Simon J. Griffin et al.
DIABETOLOGIA (2017)
Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease A Systematic Review
Matthew J. Crowley et al.
ANNALS OF INTERNAL MEDICINE (2017)
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
C. Coyle et al.
ANNALS OF ONCOLOGY (2016)
Prognosis of small cell lung cancer patients with diabetes treated with metformin
T. Xu et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2015)
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2015)
NAFLD: A multisystem disease
Christopher D. Byrne et al.
JOURNAL OF HEPATOLOGY (2015)
Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders
Sara Gandini et al.
CANCER PREVENTION RESEARCH (2014)
Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls
C. A. Bannister et al.
DIABETES OBESITY & METABOLISM (2014)
Continuation of Metformin Use After a Diagnosis of Cirrhosis Significantly Improves Survival of Patients With Diabetes
Xiaodan Zhang et al.
HEPATOLOGY (2014)
Anti-Diabetic Medications and the Risk of Hepatocellular Cancer: A Systematic Review and Meta-Analysis
Siddharth Singh et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Prognostic Significance of AMPK Activation and Therapeutic Effects of Metformin in Hepatocellular Carcinoma
Longyi Zheng et al.
CLINICAL CANCER RESEARCH (2013)
Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies
Hsiao-Ping Chen et al.
GUT (2013)
Metformin Use and All-Cause and Prostate Cancer-Specific Mortality Among Men With Diabetes
David Margel et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Metformin Reduces Endogenous Reactive Oxygen Species and Associated DNA Damage
Carolyn Algire et al.
CANCER PREVENTION RESEARCH (2012)
Metformin Inhibits Glutaminase Activity and Protects against Hepatic Encephalopathy
Javier Ampuero et al.
PLOS ONE (2012)
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
G. Vernon et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Management of Hepatocellular Carcinoma: An Update
Jordi Bruix et al.
HEPATOLOGY (2011)
Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents The TONIC Randomized Controlled Trial
Joel E. Lavine et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Impact of Metformin on the Prognosis of Cirrhosis Induced by Viral Hepatitis C in Diabetic Patients
Gisele Nkontchou et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Therapeutic Trials in Nonalcoholic Steatohepatitis: Insulin Sensitizers and Related Methodological Issues
Vlad Ratziu et al.
HEPATOLOGY (2010)
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis
R. Loomba et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Prevention and management of Gastroesophageal varices and variceal Hemorrhage in cirrhosis
Guadalupe Garcia-Tsao et al.
HEPATOLOGY (2007)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease
E Bugianesi et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Dysregulation of the TSC-mTOR pathway in human disease
K Inoki et al.
NATURE GENETICS (2005)
分享论文
